Skip to main content
. 2012 Jul 24;2012:685951. doi: 10.1155/2012/685951

Table 2.

Patient demographics.

Overall p16 negative p16 positive P value
n 106 36 70
Mean age (years) 58.1 59.2 57.5 0.461
Median followup (months) 27.2 26.9 37.2
Gender
 Male 83 (78.3%) 25 (69.4%) 58 (82.9%) 0.113
 Female 23 (21.7%) 11 (30.6%) 12 (17.1%)
Received chemotherapy (%) 65 (61.3%) 18 (50.0%) 47 (67.1%) 0.086
Habits (%)
 Tobacco use 83 (78.3%) 35 (97.2%) 48 (68.6%) 0.000††
 Alcohol use 68 (64.2%) 29 (80.6%) 39 (55.7%) 0.011
Primary site (%) 0.002††
 Tonsil 58 (54.7%) 20 (55.6%) 38 (54.3%)
 Base of tongue 41 (38.7%) 10 (27.8%) 31 (44.3%)
 Soft palate 6 (5.7%) 6 (16.7%) 0 (0.0%)
 Pharyngeal wall 1 (0.9%) 0 (0.0%) 1 (1.4%)
Primary tumor classification 0.467††
 T1 29 (27.4%) 9 (25.0%) 20 (28.6%)
 T2 52 (49.1%) 16 (44.4%) 36 (51.4%)
 T3 12 (11.3%) 4 (11.1%) 8 (11.4%)
 T4 13 (12.3%) 7 (19.4%) 6 (5.6%)
Lymph node classification 0.393††
 N0 14 (13.2%) 7 (19.4%) 7 (10.0%)
 N1 21 (19.8%) 8 (22.2%) 13 (18.6%)
 N2a 9 (8.5%) 1 (2.8%) 8 (11.4%)
 N2b 40 (37.7%) 15 (41.7%) 25 (35.7%)
 N2c 18 (17.0%) 4 (11.1%) 14 (20.0%)
 N3 4 (3.8%) 1 (2.8%) 3 (4.3%)
Stage group 0.711††
 I 0 (0.0%) 0 (0.0%) 0 (0.0%)
 II 10 (9.4%) 5 (13.9%) 5 (7.1%)
 III 23 (21.7%) 7 (19.4%) 16 (22.9%)
 IVA 69 (65.1%) 23 (63.9%) 46 (65.7%)
 IVB 4 (3.8%) 1 (2.8%) 3 (4.3%)
 IVC 0 (0.0%) 0 (0.0%) 0 (0.0%)
Histology 0.007††
 Well differentiated 5 (4.7%) 2 (5.6%) 3 (4.3%)
 Moderately differentiated 33 (31.1%) 15 (41.7%) 18 (25.7%)
 Poorly differentiated 29 (27.4%) 12 (33.3%) 17 (24.3%)
 Not otherwise specified 9 (8.5%) 5 (13.9%) 4 (5.7%)
 Basaloid 26 (24.5%) 2 (5.6%) 24 (34.3%)
 Lymphoepithelioma 1 (0.9%) 0 (0.0%) 1 (1.4%)
 Papillary 3 (2.8%) 0 (0.0%) 3 (4.3%)

t-test.

Chi-square test.

††Fisher's exact test.